TNYA - שווי שוק לנפח מכירות Tenaya

לוגו תאגידי של חברת Tenaya Therapeutics Inc (TNYA)

Tenaya Therapeutics generates revenue based on the commercial implementation of gene therapy to combat heart failure. Unique patents on gene delivery methods create significant barriers to entry for competitors, as evidenced by the price-to-sales ratio, which is currently fixed at 26.00. Stringent FDA regulations and colossal R&D expenditures render this moat virtually insurmountable.

TNYA: מכפיל P/S Tenaya Therapeutics 08.05.2026 - 16.11.2026

פילוחים אנליטיים של חברת tenayatherapeutics.com (TNYA)

- מחיר מניה וקונצנזוס הערכת שווי:
- סטטיסטיקת שווי שוק:
ניתוח פונדמנטלי של החברה:Tenaya Therapeutics Inc - TNYA
מוצרים מוגמרים של Tenaya Therapeutics

Tenaya Therapeutics specializes in developing innovative gene therapies for the treatment of hereditary heart pathologies, which drives the high value of its intellectual assets. An analysis of the company's P/S ratio allows for the correlation of market capitalization with annual revenue, determining the degree of overpayment for the business and helping investors timely identify zones of overvaluation or undervaluation of the asset before making a purchase decision.